anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For critically ill patients with non-small cell lung cancer (NSCLC) in need of life-saving treatment, there is currently no reported evidence regarding the use of medication specifically targeting epidermal growth factor receptor ( EGFR ) p.C797S mutation, which is known to cause resistance to third-generation tyrosine kinase inhibitors (TKIs). Our report aims to investigate and explore treatment strategies to overcome resistance associated with EGFR p.C797S mutation in order to provide potential therapeutic options for these patients. Here, we reported two cases with NSCLC who initially harbored an EGFR -sensitive mutation and were both treated with osimertinib, a third-generation TKI. Next-generation sequencing tests conducted prior to the initiation of fifth-line therapy in critically ill patients revealed the presence of EGFR p.C797S mutations in both patients, suggesting acquired resistance. In the course of fifth-line therapy, the administration of a combination of brigatinib and cetuximab proved vital in saving critically ill patients, moderately extending their overall survival period. Our findings suggested that a combined regimen of brigatinib and cetuximab could serve as a potentially life-saving therapeutic strategy for critically ill patients with NSCLC, particularly those demonstrating EGFR p.C797S-mediated resistance. Further studies, however, are required to validate and expand upon these promising findings.
Aqueous solutions of antimony salts of organic acids are stabilized by the addition of polyhydric alcohols containing at least four hydroxy groups.  Thus, the addition of cane sugar, glucose, mannitol, lactose or xylose to an aqueous solution of antimony lactate increases its stability.  The Specification as open to inspection under Sect. 91 (3) (a) describes the antimony compounds employed as "antimony salts which do not contain antimony bound to a carbon atom."  This subject-matter does not appear in the Specification as accepted.ALSO:Aqueous solutions of antimony salts of organic acids or of salts of antimonic acid with amines are stabilized by the addition of polyhydric alcohols containing at least four hydroxy groups. Thus, the addition of cane sugar, glucose, mannitol, lactose, or xylose to aqueous solutions of antimony lactate or of the salts of antimonic acid described in Specification 309,184, [Class 2 (iii), Dyes &c.], increases their stability.  The solutions are suitable for therapeutic application.  According to the example, the diethylamine salt of antimonic acid is dissolved with glucose in water; it can be sterilized without becoming turbid.  The Specification as open to inspection under Sect. 91 (3) (a) describes the antimony compounds employed as "antimony salts which do not contain antimony bound to a carbon atom" and contains an example of the preparation of an aqueous solution containing glucose and the sodium salt of antimony pyrocatechin disulphonic acid.  This subject-matter does not appear in the Specification as accepted.ALSO:Aqueous solutions of antimony salts of organic acids or of salts of antimonic acid with amines are stabilized by the addition of polyhydric alcohols containing at least four hydroxy groups. Thus, the addition of cane sugar, glucose, mannitol, lactose or xylose to aqueous solutions of antimony lactate or of the salts of antimonic acid described in Specification 309,184, [Class 2 (iii), Dyes &c.], increases their stability.  The solutions are suitable for therapeutic application.  According to the example, the diethylamine salt of antimonic acid is dissolved with glucose in water; it can be sterilized without becoming turbid.  The Specification as open to inspection under Sect. 91 (3) (a) describes the antimony compounds employed as "antimony salts which do not contain antimony bound to a carbon atom" and contains an example of the preparation of an aqueous solution containing glucose and the sodium salt of antimony pyrocatechin disulphonic acid.  This subject-matter does not appear in the Specification as accepted.
A cosmetic method for reducing the body odour caused by perspiration in which a cosmetic agent is applied to human skin and remains at the application site for at least an hour. The cosmetic agent comprises at least one protein hydrolysate selected from wheat protein hydrolysates, soy protein hydrolysates, rice protein hydrolysates, pea protein hydrolysates, hydrolysed keratin and protein hydrolysates from the seeds of Adansonia digitata or mixtures thereof and at least one active ingredient selected from deodorant active agents, antiperspirant aluminium salts, antiperspirant aluminium-zirconium salts and mixtures thereof. The protein hydrolysate may comprise 1.0-40% of the cosmetic agent. The deodorant active agent may be selected from silver and/or zinc salts, aromatic alcohols, 1,2-alkandediols with 5-12 carbon atoms, triethyl citrates, active ingredients against exoesterases, cationic phospholipids, odour absorbers, deodorant ion exchangers, antimicrobial agents, prebiotic components, chelating agents, sorbitan caprylate and/or glucono-delta-lactone and mixtures thereof and may comprise 0.0005-20% of the cosmetic agent. The antiperspirant aluminium salt or aluminium-zirconium salt may comprise 0.1-35% of the cosmetic agent. The cosmetic agent may comprise at least one hydrolysed starch.
Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.
Hypertension is the driving risk factor for disparities in mortality and life expectancy between African Americans and Whites. Hypertension self-management (including blood pressure monitoring, diet, exercise, and other lifestyle changes) is critical for improving hypertension control, and prior interventions have emphasized promoting patient-level behavior change to improve self-management adherence. Though family members make substantial contributions to hypertension self-management for African Americans, family support is consistently underutilized by current hypertension self-management interventions. Family-based interventions for improving self-management are effective for other chronic conditions, including for African Americans. Evidence has demonstrated the unique and important role of family support in African Americans' hypertension management, and African Americans' preferences for the direct involvement of family in hypertension interventions. The study team will develop a family-based hypertension self-management intervention ("Walk Together") for African Americans with uncontrolled hypertension that integrates community-based participatory perspectives in the specifics of the intervention. The study team will pilot trial the culturally-adapted intervention in a primary care setting in order to examine the feasibility and acceptability of the Walk Together protocol.
A system and method for predicting an illness, death or other abnormal condition of an animal is disclosed. A record for the animal including a monitored temperature time series of monitored temperature values that are indicative of a temperature of the animal over a given time period is provided. The monitored temperature time-series is a temperature pattern that includes two or more cycles that are defined by a distance between a given peak of the temperature pattern and a successive peak of the temperature pattern, or a distance between a given valley of the temperature pattern and a successive valley of the temperature pattern. The monitored temperature time-series is analyzed. Based on the analysis, a prediction of the illness, death or other abnormal condition of the animal within a given time duration of the given time period is made. A user of the system is notified of the prediction.
The invention concerns 4Fe-4S oxidoreduction protein 9 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes 4Fe-4S oxidoreduction protein 9.
Aging is associated with slower movement patterns, a higher fall risk and a restriction in functionality. This will lead to an increase in the number of dependent elderly and a high socio-economic burden. From the age of 40, a systematic loss of muscle mass and muscle force, also known as sarcopenia, will occur. In addition, performing daily tasks requires the production of muscle force at a certain speed. The product of force and speed, power, decreases even earlier and faster than muscle force.

This power is typically measured with specialized equipment, which limits the large-scale applicability. With the help of accelerometry there is the possibility to measure power during more functional tasks and movements, which benefits the applicability, but the reliability, reference values and link with other outcome measurements related to sarcopenia has to be investigated.
While patient education materials (PEMs) across various specialties have been reported as being too difficult to read, the quality and understandability of PEMs related to scar management have not been assessed. In this study, we report the breadth of scar management interventions and readability of online PEMs authored by academic societies and university hospitals. Websites of academic medical societies and university hospitals with scar revision PEMs were assessed for relevance. PEM readability was assessed via Flesch Reading Ease, Flesch-Kincaid Grade Level, and Gunning-Fox Index scores. Understandability and actionability were evaluated using the Patient Education Material Assessment Tool (PEMAT). A total of 26 scar revision PEMs met the inclusion criteria. The most commonly mentioned scar management interventions were scar revision surgery (73%) and laser scar revision (70%), with minimal emphasis on noninvasive methods like scar massage or sun protection. Readability analysis yielded a mean Flesch reading level of 8.8. Overall, PEMAT understandability of online scar treatment PEMs was moderate, with a median of 76.0% (IQR 71.5%-80.5%). PEMs from all specialties and institution types were lacking in actionability, with median actionability of 40.8% (IQR 38.1%-60.0%). Online scar revision PEMs included a wide breadth of scar management interventions; however, the least costly interventions, such as sun protection and scar massage, were not commonly included. PEMs for scar management could be improved by simplifying language, including visual aids, and including checklists or specific steps, patients can take to take action on scar management interventions.
Stress echocardiography has become a valuable technique for the non-invasive detection of coronary artery disease. Its accuracy has been shown to be superior to that of the exercise electrocardiogram and comparable to that of myocardial perfusion imaging. The adequacy of stress echocardiography with conventional two-dimensional imaging, however, is highly dependent on operator expertise. Further, interpretation of test results is subjective and qualitative, and is based on analysis of wall motion after arbitrary segmentation of the left ventricle. Real time 3-dimensional (RT3D) echocardiography is a new technique that permits the unrestricted assessment of left ventricular wall motion and function in a single cardiac beat without ECG or respiratory gating. We hypothesize that RT3D echocardiography will have similar or greater accuracy for the detection of wall motion abnormalities compared to the conventional two-dimensional examination. We therefore propose to acquire RT3D echocardiographic images in patients with known or suspected coronary artery disease who undergo stress echocardiography. We will correlate these results with findings from coronary angiography and compare the ability of RT3D echocardiography to detect coronary artery disease with that of the conventional two-dimensional exam.
Subjects will complete 45 minutes of anaerobic exercise twice during a 7 day period. Each exercise session will be followed by 60 minutes of monitored resting recovery.
PURPOSE:To provide a novel methtrexate derivative useful as an anti-rtheumatic agent. CONSTITUTION:A compound of formula I [R1 is H, 1-4C alkyl; R2 is group of formula II (R3 is H, 1-4C alkyl; R4 is 1-4C alkyl, phenyl which may be substituted), group of formula III (R5 is H, 1-4C alkyl; n is 1-3)]. The compound of formula I is produced e.g. by the steps of reacting a compound of formula IV with a compound of formula V in the presence of an organic base and isobutyl chlorocarbonate, etc., in a solvent such as THF preferably at-20 to -15 deg.C with stirring; treating the resultant compound of formula VI with a compound of formula VII in the presence of an acid halide and dimethyl formamide in a trifluoroacetic acid, etc., under ice-cooling with stirring; stirring the reaction product in the presence of palladium-carbon in methanol, etc.; and subsequently reacting the treated product with a compound of formula VIII in DMF, etc., preferably at room temperature. For example, N-[1-[2,4- diamino-6-puteridinyl)methyl]-indoline-5-carbonyl]-gamma-anilide-L-glu tamic acid is cited.
The investigators will enroll approximately 384 female breast cancer patients. Only non-institutionalized, English literate, female breast cancer patients diagnosed within the previous ten years and younger than 50 years old at the time of diagnosis will be eligible.
Chronic obstructive pulmonary disease (COPD), a heterogeneity of chronic respiratory disease pattern, presents considerable prevalence and mortality. We aimed to explore the role and mechanisms of Jumonji domain-containing protein-3 (JMJD3) in COPD. The viability and JMJD3 expression in human bronchial epithelial cell line BEAS-2B were respectively assayed by CCK-8 assay and Western blot following stepwise exposure to increasing concentrations of cigarette smoke extract (CSE). After JMJD3 was silenced and acyl-CoA synthetase long-chain family member 4 (ACSL4) was overexpressed in CSE-treated BEAS-2B cells, cell viability, cytotoxicity, oxidative stress and total iron level were estimated using kits. ELISA estimated inflammatory levels. DCFH-DA probe and BODIPY 581/591 C11 probe were exposed to assess ROS production and lipid peroxidation. Western blot tested the expressions of ferroptosis-associated proteins. Besides, H3K27me3 and ACSL4 expressions were tested by Western blot and immunofluorescence staining. In CSE-induced BEAS-2B cells, JMJD3 expression was increased and deletion of JMJD3 improved cell viability, reduced LDH release, mitigated inflammation, oxidative stress and inhibited ferroptosis. Moreover, JMJD3 interference raised H3K27me3 expression whereas lessened ACSL4 expression in CSE-treated BEAS-2B cells. CSE exposure reduced the abundance of ACSL4 in H3K27me3 antibody. Further ACSL4 elevation reversed the impacts of JMJD3 silencing on the damage of CSE-induced BEAS-2B cells. Collectively, JMJD3 depletion might suppress ferroptosis mediated by ACSL4 to alleviate CSE-triggered inflammation and oxidative stress in BEAS-2B cells.
BACKGROUND: Dengue is caused by a positive-stranded RNA virus called dengue virus, which is spread by Aedes mosquito species. It is a fast-growing acute febrile disease with potentially lethal consequences that is a global public health problem, mostly in tropical and subtropical countries. In Ethiopia, dengue fever is understudied, although the virus is still being transmitted and viral infection rates are rising. This systematic review and meta-analysis was aimed at estimating the pooled prevalence of DENV infection in Ethiopia.
METHODS: A literature search was done on the PubMed, Hinari and Google Scholar databases to identify studies published before July, 2023. Random effects and fixed effects models were used to estimate the pooled prevalence of all three markers. The Inconsistency Index was used to assess the level of heterogeneity.
RESULTS: A total of 11 studies conducted on suspected individuals with dengue fever and acutely febrile participants were included in this review. The majority of the studies had a moderate risk of bias and no study had a high risk of bias. A meta-analysis estimated a pooled IgG prevalence of 21% (95% CI: 19-23), a pooled IgM prevalence of 9% (95%CI: 4-13) and a pooled DENV-RNA prevalence of 48% (95% CI: 33-62). There is evidence of possible publication bias in IgG but not in the rest of the markers.
CONCLUSION: Dengue is prevalent among the dengue fever suspected and febrile population in Ethiopia. Healthcare providers, researchers and policymakers should give more attention to dengue fever.
The intervention group will receive the Blueberry freeze-dried powder equivalent to 1 cup of whole Blueberries twice a day for 8 weeks (i.e. 2 cups/day).
Activation of incretin receptors by their cognate agonist augments sustained cAMP generation both from the plasma membrane as well as from the endosome. To address the functional outcome of this spatiotemporal signaling, we developed a nonacylated glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonist I-M-150847 that reduced receptor internalization following activation of the incretin receptors. The incretin receptor dual agonist I-M-150847 was developed by replacing the tryptophan cage of exendin-4 tyrosine substituted at the amino terminus with the C-terminal undecapeptide sequence of oxyntomodulin that placed lysine 30 of I-M-150847 in frame with the corresponding lysine residue of GIP. The peptide I-M-150847 is a partial agonist of GLP-1R and GIPR; however, the receptors, upon activation by I-M-150847, undergo reduced internalization that promotes agonist-mediated iterative cAMP signaling and augments glucose-stimulated insulin exocytosis in pancreatic β cells. Chronic administration of I-M-150847 improved glycemic control, enhanced insulin sensitivity, and provided profound weight loss in diet-induced obese (DIO) mice. Our results demonstrated that despite being a partial agonist, I-M-150847, by reducing the receptor internalization upon activation, enhanced the incretin effect and reversed obesity.NEW & NOTEWORTHY Replacement of the tryptophan cage (Trp-cage) with the C-terminal oxyntomodulin undecapeptide along with the tyrosine substitution at the amino terminus converts the selective glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 to a novel GLP-1R and GIPR dual agonist I-M-150847. Reduced internalization of incretin receptors upon activation by the GLP-1R and GIPR dual agonist I-M-150847 promotes iterative receptor signaling that enhances the incretin effect and reverses obesity.
Within the framework of this research, an additional stress test is performed. This stress test, consisting of 3 periods, will follow a cardiovascular assessment requested as part of a health check-up, a license application, for risk factor assessment.
A system and method for classifying the phonocardiogram (PCG) signal quality has been described. The system is configured to identify the quality of the PCG signal recording and accepting only diagnosable quality recordings for further cardiac analysis. The system includes the derivation of plurality features of the PCG signal from the training dataset. The extracted features are preprocessed and are then ranked using mRMR algorithm. Based on the ranking the irrelevant and redundant features are rejected if their mRMR strength is less. A training model is generated using the relevant set of features. The PCG signal of the person under test is captured using a digital stethoscope and a smartphone. The PCG signal is preprocessed and only the relevant set of features are extracted. And finally the PCG signal is classified into diagnosable or non-diagnosable using the relevant set of features and a random forest classifier.
It has been discovered that aberrant expression of RNF113A plays a significant role in various diseases, including esophageal cancer, hepatocellular carcinoma, and X-linked trichothiodystrophy syndrome. Nevertheless, its functional implications in cervical cancer (CC) remain unclear. The objective of this study was to investigate the role of RNF113A in both the development and prognosis of CC. To achieve this objective, a total of sixty cases were included in the follow-up investigation. The findings revealed a significant up-regulation of RNF113A protein in CC tissues compared to paired paracancerous tissues, and a high expression level of RNF113A was strongly associated with malignant phenotypes such as lymph node metastasis, differentiation degree, depth of invasion, and FIGO stage. Meanwhile, RNF113A was found to be an independent prognostic risk factor, with its high expression significantly correlating with a reduced overall survival period in patients. To elucidate the underlying cause and mechanism of the unfavorable prognosis associated with RNF113A, comprehensive functional investigations were conducted both in vitro and in vivo.Interestingly, it was revealed that RNF113A promoted migration and invasion while inhibiting apoptosis of CC cells, thereby contributing to a poor prognosis. Mechanistically, RNF113A regulated the progression and prognosis of CC through the miR197/Prp19/p38Mark signaling pathway. Overall, our findings underscore the potential clinical significance of RNF113A as an unfavorable prognostic factor in CC.
Standard treatment of the infant with gastroschisis consists of , the bowel being reduced into the abdomen, when possible,and the abdominal wall defect being closed in the operating room. When complete reduction of the eviscerated contents is not possible, a silastic " silo" is sewn on the abdominal wall and its contents are gradually reduced into the abdomen over several days. Once reduction is obtained, the silo is removed and the abdominal defect is closed.

Current methods of treatment are associated with significant morbidity, prolonged hospitalization, and high costs. Gastroschisis closure continues to be accompanied by a number of complications ranging from ileus, sepsis, TPN-related liver damage, necrotizing enterocolitis, respiratory insufficiency, and death. The optimal timing and method of closure, including primary versus secondary closure, continues to be debated. No prospective randomized studies to date have examined the routine use of the spring-loaded silo.
Currently there is no standard of care for relapsed or refractory primary central nervous system (CNS) lymphoma. After high-dose methotrexate or radiation therapy, the best approach to relapsed disease is undefined. Common practice is the regimen RBEAM as a conditioning regimen in this patient population prior to transplantation. The RBEAM regimen includes R (rituximab), B (BCNU), E (etoposide), A (Ara-C (cytarabine)) and M (melphalan). In addition, dexamethasone is included in the regimen although not noted in the RBEAM mnemonic. However, the melphalan used in this combination is not thought to have much CNS penetration. Therefore, temozolomide, an alkylating agent known to penetrate the CNS and approved by the FDA for brain tumors will be used and evaluated in this study instead of melphalan.

The aim of this study is to determine an effective and safe dose of temozolomide orally administered to patients with relapsed primary CNS lymphoma over the 5 days preceding autologous stem-cell transplantation. The hope is that the conditioning regimen DRBEAT \[D (dexamethasone) (R (rituximab), B (BCNU), E (etoposide), A (Ara-C (cytarabine)) and T (temozolomide)\] will significantly improve the survival of patients with relapsed CNS lymphoma.